Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Core Insights - Eli Lilly and Company will present data on its oncology pipeline, including Verzenio, Retevmo, olomorasib, and imlunestrant, at the 2024 ASCO Annual Meeting from May 31 to June 4 in Chicago [1] - An investor event will be held on June 2 to update stakeholders on Lilly's oncology strategy and pipeline [1] Verzenio (abemaciclib) - A pivotal Phase 3 postMONARCH study will report on the efficacy of Verzenio in combination with fulvestrant for HR+, HER2- advanced breast cancer patients who have progressed on prior treatments [2] - Verzenio is the first CDK4/6 inhibitor approved for high-risk early breast cancer and has shown significant overall survival benefits in clinical trials [6][8] Retevmo (selpercatinib) - Results from the Phase 1/2 LIBRETTO-121 study will be presented, focusing on the safety and efficacy of Retevmo in pediatric patients with advanced solid tumors harboring RET alterations [2] - Retevmo is indicated for various cancers with RET gene fusions and has shown promising results in clinical settings [28][29] Olomorasib (investigational KRAS G12C inhibitor) - Updated results from a Phase 1/2 study will be shared, evaluating olomorasib's safety and efficacy in KRAS G12C-mutant advanced non-small cell lung cancer [3] - Olomorasib is designed to target KRAS G12C mutations, which are prevalent in various solid tumors [48][49] Imlunestrant (investigational oral SERD) - Imlunestrant will be presented in studies assessing its use in combination with HER2-directed therapy for advanced breast cancer [4] - This investigational drug aims to overcome resistance to endocrine therapy in ER+/HER2- breast cancer patients [47]